Supplementary Fig. GST Addition rANX II Cisplatin(mM) 0 5 10 0 5 10 Bcl-xL Bax Actin GST 2.5 rANX II 2.0 1.5 Relatieve amount (Bcl-xL/Bax) 1.0 0.5 0 0 10 5 Cisplatin (mM) Supplementary Fig. Expression of Bcl-xL and Bax proteins following cisplatin treatment in rANX II-supplemented AsPC-1 cells. AsPC-1 cells were cultured in the presence of rANX II (0.8 µg/mL) and GST (0.027 µg/mL) for 24 h, and then treated with cisplatin at the indicated concentration. Whole cell lysates were prepared, and the expression levels of Bcl-xL, Bax, and actin proteins were analyzed by immunoblotting as described in Materials and Methods. Results depicted in the figure are representative of findings from three independent experiments. Protein levels of Bcl-xL and Bax were normalized to actin levels, and ratios of Bcl-xL to Bax levels are presented as relative values to those of control cells without cisplatin treatment (GST alone). Data are presented as mean ± SD.